CureMatch, a digital health company focusing on personalized medicine and combination therapy in oncology, today announced that it has closed its bridge round to Series A financing.

CureMatch is the only company to offer a data-driven report that scores combinations of cancer drugs that are tailored for individual patients. The report is generated using CureMatch's Decision Support System, which can analyze millions of cancer treatment options with its proprietary algorithms and evidence-based, custom-curated databases of genomics and proteomics information.

CureMatch was founded less than two years ago, launched its product earlier this year, and has been seeking seed investment as it expands sales and marketing efforts. The bridge round was oversubscribed, with Serra Ventures and tech entrepreneur Phil Trubey as major investors. CureMatch is now starting discussions with Series A investors.

Serra Ventures is a venture capital firm investing in early stage information technology, and devices/instrumentation technologies. Phil Trubey founded Websense, Inc. (now Forcepoint), which was acquired by Raytheon in 2015 for $1.8 billion.

"CureMatch represents a unique, breakthrough opportunity in the treatment of cancer, a disease that touches all of our lives in some way," said Steve Beck, Managing Partner at Serra Venture's San Diego office. "The company's solution resides at the intersection of precision medicine and actionable intelligence extracted from big data. We're confident that the CureMatch team is poised to lead the way in personalized cancer treatment, and we are thrilled to add them to the Serra Ventures' portfolio."

"I've been following CureMatch's remarkable progress over the past several months, and am very impressed by their team and their unique technology," said Phil Trubey. "I believe that this company is going to have a tremendous impact on how cancer is treated."

In addition to its success in attracting financing, CureMatch has also been recognized as one of the top startups in San Diego. Last week CureMatch was selected as one of 15 companies in World Trade Center San Diego's prestigious MetroConnect program, which provides assistance and a $10,000 award to help companies expand global sales. Previously, CureMatch was selected by the San Diego Venture Group as one of its 2017 Cool Companies. SDVG's list of Cool Companies are those determined to be "venture-ready" and among the "fastest-growing, most exciting startups in Southern California." In the past two months, CureMatch has been featured on the KUSI Evening News in its weekly segment "Health Living", as well as Xconomy, the San Diego Business Journal, Hatch Magazine, NBC 7 San Diego, and many other media outlets.

"CureMatch is at a point of its growth where our partnership with Serra Ventures will help us to further accelerate the deployment of our personalized cancer treatment technology," said Blaise Barrelet, CEO of CureMatch. "This will allow us to improve patient outcomes now instead of tomorrow."

About CureMatch

CureMatch™, Inc. is a San Diego-based digital health company focused on personalized medicine and combination therapy in oncology. CureMatch's Decision Support System guides oncologists in the selection of cancer drugs that are customized for individual patients based on their molecular tumor profile. CureMatch enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options. For more information, visit www.curematch.com